Skip to content
Search
Please enter at least 3 characters.

Latest Stories

MHRA increases scrutiny of valproate prescribing to protect patients from its side effects

MHRA increases scrutiny of valproate prescribing to protect patients from its side effects

The epileptic drug may cause serious harm to unborn babies, if taken during pregnancy, and impair fertility in males

The Medicines and Healthcare products Regulatory Agency (MHRA) has instructed healthcare organisations to start planning for implementing new regulatory measures to reduce the known harms of sodium valproate, the drug used to treat epilepsy and bipolar disorder.


Valproate use during pregnancy can cause serious harm to the unborn child, as well as impair fertility in males, it said.

The UK's medicines regulator has asked healthcare professionals to stop prescribing the antiepileptic drug to new patients (male or female) younger than 55 years from January 2024, unless “there is no other effective or tolerated treatment” or there are compelling reasons that “the reproductive risks do not apply.”

Girls and women of child-bearing potential who are currently taking valproate will be reviewed at their next annual specialist review, using a revised Annual Risk Acknowledgement Form, and a second opinion’s signature would be required if the patient is to continue with the drug.

A similar system will be introduced later in 2024 for male patients currently taking valproate.

The regulatory changes have been recommended by the Commission on Human Medicines, comprising of representatives from across the healthcare system, to increase scrutiny of valproate prescribing and ensure that drug is only used when the benefits outweigh the risk.

As advised by the independent expert group, these measures would be introduced in a phased manner to ensure ongoing patient care is not disrupted.

Health Minister Maria Caulfield expressed her sympathies for all those affected by the side effects of sodium valproate.

“These regulatory measures will help to further improve patient safety and ensure valproate is only used when the benefits outweigh the risk,” she said.

MHRA Chief Safety Officer, Dr Alison Cave cautioned that valproate should only be used in girls and women of child-bearing potential if a pregnancy prevention programme is in place.

“To better protect patients from these harms, we are taking robust regulatory action to ensure greater scrutiny of valproate prescribing. Valproate should only be used when no other treatment is effective,” she said.

Dr Alison also urged patients who are on valproate to attend any appointments offered over the next year to discuss their treatment plan and talk to a healthcare professional if they are concerned.

But no one should stop taking valproate without advice from a specialist, she added.

Side effects of Valproate 

“Valproate is a highly teratogenic medicine that also carries known risks to male fertility – it is therefore vital valproate is only used when there is no other effective or tolerated treatment option,” said Professor Munir Pirmohamed, Chair of The Commission on Human Medicines.

“We have consulted with patients and healthcare professionals with experience of valproate to inform our recommendations and to ensure that they are introduced in a way that does not disrupt ongoing patient care,” he added.

According to Patient Safety Commissioner Dr Henrietta Hughes, exposure to teratogens can cause physical and learning disabilities in children.

To dramatically reduce the number of babies exposed to these harmful substances, all organisations must bring in new measures from January 2024, the expert stated.

It is estimated that one in nine babies exposed to valproate during pregnancy have major birth defects, while it causes neurological disorder in as many as 4 in 10 babies.

More For You

AAH Pharmaceuticals introduces 20 new electric vans to its delivery fleet

18 vans have been added to the AAH DC in Ruislip, and another 2 to their branch in Glasgow

Photo credit: AAH

AAH Pharmaceuticals adds 20 new electric vans to reduce carbon emissions

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced 20 new electric vans to its delivery fleet, marking a significant step forward in its Carbon Reduction Plan, which is aligned to the NHS net zero targets.

Eighteen of the new electric vehicles have been deployed at the AAH distribution centre in Ruislip, with the remaining two now in operation at its Glasgow branch.

Keep ReadingShow less
Numark launches new digital consultation platform to support independent prescribers

Harry McQuillan, Chairman of Numark

Numark launches DigiPharma to empower independent prescribers

Numark has launched a new digital consultation platform, called DigiPharma, designed to support both current and future independent prescribers (IPs) in making full use of their qualifications.

The revolutionary cloud-based prescribing recording platform is now available exclusively to Numark members.

Keep ReadingShow less
Operation Subaru:

Some of the medicines seized in raids today. Credit: MHRA

12 arrested in MHRA’s biggest medicines trafficking crackdown

Twelve people have been arrested in a series of dawn raids across the West Midlands and the Northwest of England today (29 April), as part of the biggest criminal investigation ever undertaken by the Medicines and Healthcare products Regulatory Agency (MHRA) into organised medicines trafficking.

The suspects were detained on suspicion of involvement in organised crime, conspiracy to sell or supply controlled and unlicensed medicines, and money laundering.

Keep ReadingShow less
Sukhi Basra named NPA vice-chair in historic leadership update with Olivier Picard as new chair

Olivier Picard steps up as NPA chair, Basra as vice-chair

Olivier Picard named new NPA chair

The National Pharmacy Association (NPA) has announced Olivier Picard as the organisation’s new chair.

Picard replaces Nick Kaye whose term comes to an end this week.

Keep ReadingShow less
 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less